BioRestorative Therapies (NASDAQ:BRTX) has announced that the Israel Patent Office has issued a Notice of Allowance for a new patent application, covering several fundamental elements of its allogeneic, off-the-shelf ThermoStem platform.
This marks the company’s 14th international patent for its ThermoStem technology platform. The patent encompasses non-naturally occurring, three-dimensional brown adipose derived stem cell (BADSC) aggregates; an encapsulation system comprising the non-naturally occurring three-dimensional brown adipose derived stem cell aggregates; a method of making a non-naturally occurring three-dimensional BADSC aggregates; and a method of treating patients with certain disorders.
“We believe that our ThermoStem-based BADSCs hold tremendous promise to deliver a superior efficacy and tolerability profile over GLP-1 drugs,” said Lance Alstodt, CEO of BioRestorative.
“This latest patent issuance demonstrates our strong commitment to protecting the innovation of our ThermoStem program and the significant potential commercial opportunity that it represents for ourselves and any current and/or future potential licensing partners. And, given Israel’s global prominence in stem cell research, we are particularly excited by this latest patent issuance,” he added.
In May 2024, BioRestorative revealed the development of a novel exosome-based biologic program targeting obesity, announcing plans to begin the formal FDA process for this ThermoStem-based candidate by filing a Drug Master File. Shortly after, BioRestorative reported that it had entered substantive discussions with an undisclosed commercial-stage regenerative medicine company regarding a potential license of its allogeneic, off-the-shelf ThermoStem metabolic intellectual property. While discussions are ongoing, no assurance can be given that a license agreement will be entered into, whether on commercially reasonable terms or otherwise.
